Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics (ADMA)
NASDAQ:ADMA
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.16Last Year’s EPS
0.09Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 03, 2025
|% Change Since: 27.98%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong positive outlook for ADMA Biologics, with significant revenue growth and strategic advancements in high-titer plasma supply and ASCENIV's market potential. However, there is some uncertainty with pending FDA approval and delayed audit completion.Company Guidance
During the ADMA Biologics Fourth Quarter and Full Year 2024 Financial Results and Business Update Conference Call, the company reported substantial financial growth and revised its guidance upwards. Total revenues reached $426.5 million for 2024, marking a 65% increase year-over-year, and adjusted EBITDA grew by 309% to $164.6 million. For 2025, ADMA projects revenues to exceed $490 million with adjusted EBITDA surpassing $225 million, while 2026 guidance anticipates revenues of $605 million and adjusted EBITDA of $305 million. The company also raised adjusted net income projections to more than $175 million in 2025 and $235 million in 2026. Margin expansion is expected as the revenue mix shifts towards ASCENIV, which is seen as a potential $1 billion opportunity with brand durability through at least 2035. ADMA highlighted a transformative milestone with third-party high-titer plasma supply contracts, which could enable total annual revenue to potentially exceed $1 billion before 2030. The anticipated approval of an enhanced yield production process could further increase production output by approximately 20%, potentially driving additional financial upside.Exceptional Financial Growth
Total revenues reached $426.5 million, reflecting an increase of 65% year-over-year. Adjusted EBITDA grew to $164.6 million, representing a growth rate of 309% from the previous year.
ASCENIV's Market Potential
ASCENIV's forward-looking demand metrics are making new all-time highs into 2025. The company anticipates continued margin expansion and expects ASCENIV alone could surpass $1 billion in total annual revenue.
High-Titer Plasma Supply Contracts
Third-party high-titer plasma supply contracts have been executed, marking a transformative milestone and paving the way for long-term top-tier growth for ADMA.
Strong Financial Position
Total cash holdings exceeded $103 million at year-end 2024, representing a net cash surplus relative to the $75 million of total debt currently outstanding.
Projected Revenue and EBITDA Growth
The company expects total revenue to exceed $490 million in 2025 and $605 million in 2026, with adjusted EBITDA projected to surpass $225 million and $305 million respectively.
---
ADMA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ADMA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 03, 2025 | $15.83 | $17.01 | +7.45% |
| Nov 07, 2024 | $19.72 | $22.62 | +14.71% |
| Aug 08, 2024 | $12.19 | $15.96 | +30.93% |
| May 09, 2024 | $6.93 | $8.81 | +27.13% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does ADMA Biologics (ADMA) report earnings?
ADMA Biologics (ADMA) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is ADMA Biologics (ADMA) earnings time?
ADMA Biologics (ADMA) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ADMA EPS forecast?
ADMA EPS forecast for the fiscal quarter 2025 (Q1) is 0.16.
---